Disseminated herpes zoster infection 16 months after last intake of alemtuzumab: potential long-term adverse effects.

Albrecht, L J; Moelleken, M; Dissemond, J

Disseminated herpes zoster infection 16 months after last intake of alemtuzumab: potential long-term adverse effects.

Albrecht, L J; Moelleken, M; Dissemond, J.

Affiliation

Albrecht LJ; Department of Dermatology, Venerology and Allergology, University of Essen, Germany.
Moelleken M; Department of Dermatology, Venerology and Allergology, University of Essen, Germany.
Dissemond J; Department of Dermatology, Venerology and Allergology, University of Essen, Germany.

Clin Exp Dermatol ; 46(3): 550-552, 2021 Apr.

Article in En | MEDLINE | ID: mdl-32810347

Subject(s)

Alemtuzumab/adverse effects; Herpes Zoster/diagnosis; Immunocompromised Host; Immunosuppressive Agents/adverse effects; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Multiple Sclerosis, Relapsing-Remitting/immunology; Adult; Herpes Zoster/drug therapy; Humans; Male; Risk Factors; Time Factors; Virus Activation

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunocompromised Host / Multiple Sclerosis, Relapsing-Remitting / Alemtuzumab / Herpes Zoster / Immunosuppressive Agents Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Humans / Male Language: En Journal: Clin Exp Dermatol Year: 2021 Document type: Article Affiliation country: Germany Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google